Aeron 10Mg

DESCRIPTION

Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor. Cysteinyl leukotrienes and leukotriene receptor occupation have been correlated with the pathophysiology of asthma (such as, airway edema, smooth muscle contraction and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma).

SIDE EFFECTS

Abdominal pain, thirst, headache, hyperkinesia (in young children); less commonly dry mouth, dyspepsia, oedema, dizziness, drowsiness, malaise, sleep disturbances, sleep-walking, abnormal dreams, anxiety, agitation (including aggressive behavior or hostility), depression, psychomotor hyperactivity (including irritability end restlessness), paraesthesia, hypoesthesia, seizures, arthralgia, myalgia (including muscle cramps), epistaxis, bruising; rarely palpitation, tremor, disturbance in attention, memory impairment, increased bleeding tendency: very rarely hepatic eosinophilic infiltration, hepatic disorders, hallucinations, suicidal thoughts and behavior, disorientation, Chrug-Strauss syndrome (see notes above), erythema nodosum, erythema multiforme.

CONTRAINDICATION

Montelukast is contraindicated to patients with hypersensitivity to any component of this product.

DRUG INTERACTION

Montelukast has been administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma with no appropriate increase in adverse reactions. Cytochrome P-450 inducers: Although Phenobarbital induces hepatic metabolism, no dosage adjustment for Montelukast is recommended. It is reasonable to employ appropriate clinical monitoring when potent cytochrome P-450 enzyme inducers, such as phenobarbital or rifampin are co-administered with Montelukast.

OVERDOSE

There were no adverse experiences reported in the majority of overdose reports. The most frequent adverse experiences observed were thirst, mydriasis, hyperkinesia and abdominal pain. In the event of overdose, it is reasonable to employ the usual supportive measures; e.g. remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring and institute supportive therapy, if required. 

Healthcare Pharmaceuticals Ltd